Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REal-world Study of Trastuzumab deruXtecan in Patients With unresectabLe or Metastatic Breast Cancer Expressing HER2-lOw From BulgaRia and SlovEnia (EXPLORE)

NCT06727227 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06727227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06727227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REal-world Study of Trastuzumab deruXtecan in Patients With unresectabLe or Metastatic Breast Cancer Expressing HER2-lOw From BulgaRia and SlovEnia (EXPLORE)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
January 29, 2025
Completion date
October 31, 2027
Enrollment
138 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer